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1. Introduction 
rmnlunological response to hepatitis B surface 
antigen (HB,Ag)and to other viral antigens varies con- 
siderably not only among species, but also among 
individuals of the same species [ I]. High antibody titres 
and a relatively uniform response can often be achieved 
by the use of adjuvants. However, complete Freund’s 
adju~nt , lipopolysaccharide endotoxins and poIyanions 
can induce local and systemic toxicity which prevents 
their application in man. On the other hand, adjuvants 
such as aluminium precipitates or water-in-oil emul- 
sions already used in human vaccines lack in efficien- 
cy and duration of effect or have unacceptable local 
reactions [2]. In this report, in view of the importance 
of developing a hepatitis B vaccine [I], we have (a) 
successfully incorporated HB$g into liposomes [3] 
and (b) tested the immunogenicity of liposomal 
HBsAg in guinea pigs. We found that liposomes act as 
powerful immunological adjuvants to the antigen. 
2. Materials and methods 
HBaAg was purified from pooled high titre positive 
donor sera by gel filtration using Sepharose 4B 
(Pharmacia) foIlowed by two successive C&l, gradient 
ultracentrifugations in-a Beckman SW SOL swinging 
rotor at 124 000 X g for 72 h. Following dialysis 
against 0.01 M sodium phosphate buffer (pH 7.2) 
containing 0.9% NaCl (PBS), the resulting prepara- 
tion consisted of the 22 nm particles. ‘2sI-labelled 
HBsAg (0.74 #Zi/rnl) was from the AUSAB kit 
(Abbott Diagnostics GmbH, Langen) and chro- 
matographed as above before use. Dimyristoylphos- 
phatidylcholine, dipalmitoylphosphatidylethanol- 
amine and sphingomyelin were purchased from Sigma 
Chemical Co. (London) and phosphatidylser~e from 
Lipid Products (Surrey). The source and grade of all 
other lipids used are given in [4]. Multilamellar 
vesicles (MLV) composed of various lipids (see 
table 1) were made as in [4,S] using 2-3 ml PBS and 
10-l 50 g HB,&g with or without radioiodinated 
HB,Ag to suspend the dry lipids (22-44 nmol phos- 
pholipid). The suspensions were sonicated in a bath- 
type sonicator for 1 .S h at 4°C. Liposome-associated 
HBsAg was separated from the free antigen (a) by 
centrifugation at 100 000 X g for 30 min at 4°C. The 
liposomal pellet containing the antigen was resus- 
pended in PBS and recentrifuged as above (b) through 
a CL-2B Sepharose (Pharmacia~ column (1 X 46 cm) 
equilibrated with PBS. Liposomal HB,Ag was eluted 
from the columns with the void volume and there 
was very little overlapping with the subsequently 
eluted unentrapped antigen. In some experiments 
HBaAg was entrapped in large unilamellar vesicles 
(LUV) prepared from phosphatidylserine 161. Free or 
Iiposome-associated HB&g was measured by solid 
phase radioimmunoassay (AUSRIA II, Abbott 
Diagn. GmbH) using a standard curve made up with 
known concentrations of HB&g provided by the kit. 
To assay total liposomal HB,Ag it was necessary to disrupt 
liposomes with sodium taurocholate (Calbiochem, 
England) which at the concentration used (3.7 mM 
final) was found superior to Triton X-300, sodium 
dodecyisulphate and Nonidet LE in terms of liposome 
sofubilization and non-interference (% inhibition) 
with the radioimmunoassay. A standard curve was 
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made with known concentratrons of HBsAg provrded each animal which were then compared at 48 h with a 
by the krt m the presence of sodmm taurocholate third area m the same region 1nJected with PBS 
Outbred, female guinea pigs (Hartley stram, 
-300 g) were divided mto groups of 6 and 
inJected with free or hposome-assocrated HB$g with 
or without Bordetclla pertusm and saponm (Brrtrsh 
Drug House) as shown m the legends to table 2 and 
frg 1 Anti-HB, trtres m the sera were determined by 
solid phase radronnmunoassay (AUSAB, Abbott 
Drag GmbH). For the measurement [7] of specific 
delayed type hypersensrtrvrty (DTH) response, 
0 5 pg and 2 0 I-18 HB,Ag m PBS was uqected mtra- 
dermally m two areas of the mterscapular region of 
3 Results and discussion 
Judging from radroactrvrty measurements, a con- 
siderable proportion of the HB.$g used was associated 
with MLV (15 4447 7%) and LUV (20 2%) hposomes 
and radrormmunoassay measurements gave similar 
results (table 1) There was no consistent evidence 
that the nature of the phosphohprd used, the molar 
ratios of the hposomal hprd components or the 
Table 1 
IncorporatIon of the hepatltls B surface antigen (HBsAg) mto hposomes 
_ 
Coniposltion of 
hposomes 
(MLV) 
PC, CHOL, DCPa 
PC, CHOL, DCP 
DPPC, CHOL, DCP 
DMPC, CHOL, DCP 
DPPE, CHOL, DCP 
SM, CHOL, DCP 
SM, DPPC 
SM, CHOL, DPPC 
(LUV) 
PS 
Molar 
rat10 
HB,Ag mcorporated mto hposomes 
Assay of Radlotmmuno- 
‘=I (%) assay (m0) 
-_ 
721 39 1 i 10 2 (7) 43 1 + 19 8 (7) 
721 265ill1(4) 
721 209r152(3) 
735 1 24 5 f 9 0 (3) 
771 15 8 
721 15 8 
7351 15 4 
771 42 4 
701 30 7 
721 46 1 
721 34 6 
735 1 47 7 
12 37 8 
121 42 4 
735 1 38 2 
202k 66(5) 13 0,lO 4 
a Llposomal HB,Ag was separated from the free antigen by molecular sieve chromatog- 
raphy With all other MLV preparations ultracentrlfugatlon was used Entrapment, 
estmlated by radloactlvlty measurements or radlolmmunoassay, IS expressed as % k SD 
of the total antigen used Numbers m parentheses denote preparations made In control 
euperlments, after eqtuhbratlon of preformed MLV with 10 pg HB,Ag (mIxed with a 
tracer) 1 3 + 1 2% (7 eupt) of the antigen was associated with chromatographlcally 
purrfied hposomes Latency m these preparations (% hposomal antigen not avadable to 
its antIbodIes) estmlated by radioimmunoassay as the difference between hposomal 
antigen measured m the presence and absence of detergent was 63 4 f 14 4 (7 experl- 
ments) Ldtcncy for 2 LUV prepdrdtlons was ml 
AbbrCvlaflOns PC, egg phosphatldylchohne, DPPC, dlpalmltoylphosphatldylcholme, 
DMPC, dmmyrlstoylphosphat~dylchohne, DPPE, d~palm~toylphospl~atldylethanolamme. 
SM, sphmgomyehn, DCP, dlcetylphosphate, CHOL, cholesterol, PS, phosphatldyl serme 
108 
Volume 102, number 1 FEBS LETTERS June 1979 
method of preparing liposomes influenced the extent 
of antigen entrapment. HBsAg was truly incorporated 
(and not simply adsorbed) in MLV obtained by 
molecular sieve chromatography: (a) in mixing 
experiments in which buffer-containing preformed 
liposomes were equilibrated with the antigen and sub- 
sequently chromatographed, only 1.2% of the antigen 
was associated with liposomes (legend to table 1). In 
contrast, adsorption of HBsAg onto a variety of MLV 
prepared by centrifugation was much greater (12-23%, 
not shown), (b) of the HBsAg incorporated into chro- 
matographed MLV, 63.4Y0 was latent (unavailable to 
its antibodies) (table 1). As HBsAg carries a lipid coat 
[8], it may be that the latter is interdigitated between 
the phospholipid molecules of the many bilayers of 
multilamellar liposomes through hydrophobic bonding 
with some or all of the antigenic sites of the HBsAg 
in the outer bilayer only being available to the anti- 
bodies. This could explain the absence of latency in 
the HBsAg incorporated in large unilamellar liposomes 
(table 1). Hydrophobic interaction of the HB.$g with 
the bilayers may in fact account for the extensive 
association of the antigen with liposomes in spite of 
its large size (16-25 nm) [9]. 
Body weights of all immunized guinea pigs 
remained comparable throughout the 80 day observa- 
tion period and by day 44 (after 3 injections) most 
animals had developed measurable anti-HB, titres 
(table 2). However, judging from the humoral conver- 
sion rates, some groups responded much earlier than 
others. Animals treated with liposomal HBSAg with 
Table 2 
Humoral conversion rate after immunization with HBsAg 
Group Day 18 Day 34 Day 44 Day 59 
conversiona conversion conversion conversion 
I O/5 l/5 l/5 214 
II O/6 l/5 315 415 
III O/6 016 416 516 
N 316 515 515 515 
V 116 516 616 616 
VI 416 616 616 616 
a Responders from total in the group 
Animals were treated on day 0,18,34 and 44 with free HB,Ag 
alone (I) or mixed with saponin (II) or B. pertussis (III) and 
with liposomal HB,Ag alone (N) or mixed with saponin Cv) 
OI B. perntssis (VI). They were bled by cardiac puncture on 
day 18, 34,44 and 59. Four animals died during sampling 
and without the adjuvants B. pertussis [2] or saponin 
[lo] (pooled groups IV-VI) exhibited an earlier 
conversion rate than respective animals treated with 
the free antigen (pooled groups I-III). The difference, 
which was highly significant (g = 22.1, P <O.OOS), 
could be attributed to liposomal entrapment per se: 
when conversion rates in groups of guinea pigs injected 
with B. pertussis (pooled groups II and VI), saponin 
(pooled groups II and V) or the antigen alone (pooled 
groups I and IV) were intercompared there was no 
significant difference (X”, = 7.01, P X.5). 
Analysis (Wilcoxon’s test) [l l] of the data from 
the groups immunized with liposomal HB,Ag (fig.1) 
Immunization of guinea pigs with 
free and liposomal HBsAg 
4 
1 
0 
I t
0 20 40 60 
Days after immunization 
n LtHB,Ag)+BP A Free HBsAg+Saponin 
l L(HBsAg) o Free HBsAg 
A L(HBsAg)+Saponin q Free HBsAg+BP 
Fig.1. Rise of anti-HB, titres in guinea pigs immunized with 
HB,Ag. Animals were treated (arrows) as described in table 2. 
Each dose (0.6 ml) given subcutaneously in both hind limbs 
contained 1.4 fig free or liposomal(0.8 mg lipid) HB,Ag and, 
when appropriate, 1.2 X 10” bacteria or 50 fig saponin. 
(0) group I; (A) group II; (0) group III; (0) group IV; (A) 
group V; (9) group VI. 
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revealed that concurrent admmlstratlon of saponm 
did not improve tltres obtained with hposomes at any 
of the time intervals examined and a slmllar conclu- 
sion could be made for B pertusm except for some 
effect on day 44 (P <0 025) In addition, at no time 
interval was there addltlonal effect of B pertusszs or 
saponm on the tltres (fig 1) obtamed with the free 
HBsAg Therefore, assessment of lmmuruzatlon was 
carried out by comparing all animals treated with 
hposomal HB$g (pooled groups IV-VI) with all 
animals treated with the free antigen (pooled groups 
I--III) It was found that multllamellar hposomes are 
a potent adluvant to the incorporated HB$g produc- 
ing a much steeper anti-HB, rise with mean anti-HB, 
tltres being at all times slgmflcantly (Wllcoxon’s test, 
P <0 001) higher than those obtained m animals 
inJected with the free antigen (fig 1) For instance, 
followmg the second challenge, the geometric mean 
tltre m the groups treated with hposomal HB.+g was 
loo-times, and after the thud challenge 750-times 
higher than m the groups inJected with the free antigen 
The ratio, however, decreased to 150-times after the 
fourth lmmumzatlon probably because response m 
the groups injected with hposomes had already 
reached its maximum, while it was still rising (fig 1) 
m the groups treated with the free antigen We have 
recently repeated this experiment m an attempt to 
compare the effect of hposomes to that of other 
ddjuvants Our results confirm the adjuvanticity of 
hposomes m the present report m terms of both 
early conversion rates and levels of antibody tltres 
tions than anunals (1 out of 15) inJected with free 
antigen (groups I-III) (P <O.OOS) Furthermore, m 
contrast to the effects of other adjuvants, no local or 
systemic reactions, such as local mflammatlon, 
granuloma formation, haemolysls or hypersensitivity 
reactions occurred at any tune during the 80 day 
period of the experiment and for several days there- 
after 
High tltres of antibodies to HB$g acquired by 
active or passive lmmumzation have been shown to 
confer lmmunrty to natural infection with hepatitis B 
virus [ 131 A vaccine against hepatitis B will be closer to 
its reahzatlon when questions of safety and efficiency 
have been answered successfully [ 141 It 1s almost 
certain that because of the relatively low and aberrant 
unmunogemclty of the HB.$g [ 1,131 or its polypep- 
tides [ 151, there will be a need for an adjuvant 
acceptable m man In this context the unmunologlcal 
adjuvant property of hposomes [ 16 ] which, alone or 
111 combmatlon with killed B pertusas, were shown 
to promote response to HBsAg may have practical 
apphcatlon Furthermore, the slmphclty of HB&g 
mcorporatlon mto hposomes composed chiefly of 
cholesterol and the apparently non-toxic lecithin 
[ 171 could render such vaccine suitable for mass 
trials 
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Table 3 
Delayed-type hypersensitivity (DTH) to HBsAg 
Group treated with Positive 
reactIona 
Group treated with Positive 
reaction 
Free HB,Ag o/4 L(HB,Ag) 315 
Free HB,Ag + saponm 115 L(HB,Ag) + sapomn O/6 
Free HB, + B per~szs O/6 L(HB,Ag) + B perrussls 515 
Total animals l/15 Total ammals 8/16 
a Ammals showmg DTH from total m the group 
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